203 related articles for article (PubMed ID: 30349972)
1. [The role of molecular imaging (PET-CT) in the diagnostic and treatment pf prostate cancer].
Mirzaei S; Knoll P; Zandieh S
Wien Med Wochenschr; 2019 Feb; 169(1-2):12-14. PubMed ID: 30349972
[TBL] [Abstract][Full Text] [Related]
2. Integrated
Lütje S; Cohnen J; Gomez B; Grüneisen J; Sawicki L; Rübben H; Bockisch A; Umutlu L; Pöppel TD; Wetter A
Nuklearmedizin; 2017 Jun; 56(3):73-81. PubMed ID: 28401244
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
Jilg CA; Drendel V; Rischke HC; Beck T; Vach W; Schaal K; Wetterauer U; Schultze-Seemann W; Meyer PT
Theranostics; 2017; 7(6):1770-1780. PubMed ID: 28529650
[No Abstract] [Full Text] [Related]
4. [PET-CT and PET-MRI of the prostate : From
Knorr K; Eiber M; Maurer T; Wester HJ; Scheidhauer K
Radiologe; 2017 Aug; 57(8):631-636. PubMed ID: 28688023
[TBL] [Abstract][Full Text] [Related]
5. Performance of
Bailey J; Piert M
Curr Urol Rep; 2017 Sep; 18(11):84. PubMed ID: 28889366
[TBL] [Abstract][Full Text] [Related]
6. [PSMA-PET/CT has to be performed in every patient with biochemical recurrence following radical prostatectomy for early tumor detection].
Kotzerke J; Böhmer D; Schlomm T; Maurer T; Beer AJ; Schmidberger H
Nuklearmedizin; 2018 Jun; 57(3):69-73. PubMed ID: 29871008
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific membrane antigen-guided salvage lymph node dissection in recurrent prostate cancer: a novel technology to detect lymph node metastases.
Maurer T; Gschwend JE; Eiber M
Curr Opin Urol; 2018 Mar; 28(2):191-196. PubMed ID: 29028767
[TBL] [Abstract][Full Text] [Related]
8.
Habl G; Sauter K; Schiller K; Dewes S; Maurer T; Eiber M; Combs SE
Prostate; 2017 Jun; 77(8):920-927. PubMed ID: 28317152
[TBL] [Abstract][Full Text] [Related]
9. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
[TBL] [Abstract][Full Text] [Related]
10. Nuclear Medicine Imaging of Prostate Cancer.
Schreiter V; Reimann C; Geisel D; Schreiter NF
Rofo; 2016 Nov; 188(11):1037-1044. PubMed ID: 27299668
[TBL] [Abstract][Full Text] [Related]
11. (68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report.
Rauscher I; Maurer T; Fendler WP; Sommer WH; Schwaiger M; Eiber M
Cancer Imaging; 2016 Jun; 16(1):14. PubMed ID: 27277843
[TBL] [Abstract][Full Text] [Related]
12. Hybrid PET/MRI in major cancers: a scoping review.
Morsing A; Hildebrandt MG; Vilstrup MH; Wallenius SE; Gerke O; Petersen H; Johansen A; Andersen TL; Høilund-Carlsen PF
Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2138-2151. PubMed ID: 31267161
[TBL] [Abstract][Full Text] [Related]
13. [PET/CT and biochemical recurrence of prostate adenocarcinoma: Added value of
Gauthé M; Belissant O; Girard A; Zhang Yin J; Ohnona J; Cottereau AS; Nataf V; Balogova S; Pontvert D; Lebret T; Guillonneau B; Cussenot O; Talbot JN
Prog Urol; 2017; 27(8-9):474-481. PubMed ID: 28576423
[TBL] [Abstract][Full Text] [Related]
14. 68Ga-PSMA PET/CT and PET/MRI in high-risk prostate cancer patients.
Sanli Y; Sanli O; Has Simsek D; Subramaniam RM
Nucl Med Commun; 2018 Oct; 39(10):871-880. PubMed ID: 30124601
[TBL] [Abstract][Full Text] [Related]
15. [Ga-68-PSMA PET/CT for prostate cancer].
Hellwig D; Moosbauer J; Eilles C
Aktuelle Urol; 2014 Nov; 45(6):457-63. PubMed ID: 25518963
[TBL] [Abstract][Full Text] [Related]
16.
Uprimny C
Wien Med Wochenschr; 2019 Feb; 169(1-2):3-11. PubMed ID: 28577076
[TBL] [Abstract][Full Text] [Related]
17. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
18. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
[TBL] [Abstract][Full Text] [Related]
19. (68)Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer.
Eiber M; Nekolla SG; Maurer T; Weirich G; Wester HJ; Schwaiger M
Abdom Imaging; 2015 Aug; 40(6):1769-71. PubMed ID: 25412869
[TBL] [Abstract][Full Text] [Related]
20. Preliminary results on response assessment using
Seitz AK; Rauscher I; Haller B; Krönke M; Luther S; Heck MM; Horn T; Gschwend JE; Schwaiger M; Eiber M; Maurer T
Eur J Nucl Med Mol Imaging; 2018 Apr; 45(4):602-612. PubMed ID: 29185010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
